Xilio Therapeutics has appointed Yariv Houvras as its chief medical officer, according to STAT's Pharmalot column. Houvras joins the company after serving as senior vice president of clinical and translational development at Tubulis, a biotech firm focused on antibody-drug conjugates.
The move adds a clinically experienced executive to Xilio's leadership team as the company continues developing its pipeline. STAT's report, part of its regular "Up and down the ladder" feature, did not include additional details about the appointment or Houvras's immediate priorities at Xilio.